February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
5 citations
,
January 2005 in “Journal of Enzyme Inhibition and Medicinal Chemistry” New steroids were effective in blocking male hormone receptors in hamster prostates.
1 citations
,
March 2023 in “Science Translational Medicine” Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.
11 citations
,
August 2014 in “PLoS ONE” GFRα2 is essential for controlling neuron size but not for target innervation in certain sensory neurons.
2 citations
,
November 2018 in “Indian Journal of Pharmaceutical Education” The developed model can predict effective 5-alpha-reductase enzyme inhibitors.
1 citations
,
December 2011 in “Arzneimittelforschung” CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
47 citations
,
November 1982 in “Journal of Cardiovascular Pharmacology” Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.
2 citations
,
November 2017 in “Elsevier eBooks” Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.
4 citations
,
September 2025 in “Biomolecules” The effect of GLP-1 RAs on erectile function is unclear and needs more research.
December 2025 in “Naunyn-Schmiedeberg s Archives of Pharmacology” Agomelatine may help reduce benign prostatic hyperplasia by blocking certain inflammatory pathways.
25 citations
,
December 2018 in “Journal of Investigative Dermatology” TRPV4 slows hair growth by affecting hair follicle cells.
16 citations
,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
18 citations
,
October 2010 in “Bioorganic & Medicinal Chemistry Letters” New hybrid compound found to effectively prevent hair loss.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
2 citations
,
November 2025 in “British Journal of Pharmacology” Daprodustat, combined with PAβN, could be a new antibacterial treatment.
18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
February 2023 in “European Journal of Medical Research” Certain existing drugs, like glycopyrronium and botulinum toxin type A, may help treat excessive sweating.
14 citations
,
March 2017 in “Brain research” Progesterone and its byproducts control a specific receptor in the brain independently of progesterone receptors, affecting conditions related to the menstrual cycle.
64 citations
,
March 2008 in “Neuropsychopharmacology” 28 citations
,
November 2004 in “Endocrinology” SARMs may offer benefits by boosting muscle effects without unwanted side effects.
February 2026 in “The Journal of Sexual Medicine” GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.
3 citations
,
January 2023 in “Clinical cancer investigation journal” Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.
8 citations
,
October 2016 in “Journal of Investigative Dermatology” MR antagonists may improve skin health and wound healing, especially in aging.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
45 citations
,
April 2021 in “Current Treatment Options in Oncology” ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
1 citations
,
November 1975 in “PubMed” GRF is not safe for tubal occlusion.
12 citations
,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
12 citations
,
June 2001 in “Bioorganic & Medicinal Chemistry” Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.